Physician profile
Robert F Bundy
NPI 1518946458
$11,319.24
in general payments reported to CMS, 2019-2025
58 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $1,292 · 2021: $1,699 · 2022: $1,762 · 2023: $1,768 · 2024: $1,979 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,437.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,307.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,173.46 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,140.72 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $1,031.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $937.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $593.16 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.46 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $483.91 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $428.32 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $298.59 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $244.66 | 2021-2024 | Nexletol |
| Lilly USA, LLC | $224.73 | 2019-2024 | Jardiance, Emgality, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $209.11 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $189.18 | 2019-2022 | |
| Abbott Laboratories | $175.83 | 2022-2024 | Freestyle Libre 3 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.